State Of New Jersey Common Pension Fund D buys $84,101,450 stake in Abbott Laboratories (ABT)

Abbott Laboratories (ABT) : State Of New Jersey Common Pension Fund D scooped up 200,000 additional shares in Abbott Laboratories during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 2, 2016. The investment management firm now holds a total of 1,871,000 shares of Abbott Laboratories which is valued at $84,101,450.Abbott Laboratories makes up approximately 0.37% of State Of New Jersey Common Pension Fund D’s portfolio.

Other Hedge Funds, Including , Ancora Inverness reduced its stake in ABT by selling 523 shares or 1.62% in the most recent quarter. The Hedge Fund company now holds 31,705 shares of ABT which is valued at $1,425,140. Abbott Laboratories makes up approx 0.53% of Ancora Inverness’s portfolio.Wheatland Advisors Inc reduced its stake in ABT by selling 198 shares or 2.74% in the most recent quarter. The Hedge Fund company now holds 7,038 shares of ABT which is valued at $316,358. Abbott Laboratories makes up approx 0.17% of Wheatland Advisors Inc’s portfolio. Cg Asset Management sold out all of its stake in ABT during the most recent quarter. The investment firm sold 11,300 shares of ABT which is valued $493,471.Chevy Chase Trust Holdings reduced its stake in ABT by selling 2,634 shares or 0.19% in the most recent quarter. The Hedge Fund company now holds 1,386,786 shares of ABT which is valued at $58,092,466. Abbott Laboratories makes up approx 0.32% of Chevy Chase Trust Holdings’s portfolio.

Abbott Laboratories closed down -0.24 points or -0.53% at $45.02 with 76,57,947 shares getting traded on Monday. Post opening the session at $45.06, the shares hit an intraday low of $44.88 and an intraday high of $45.41 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.

On the company’s financial health, Abbott Laboratories reported $0.55 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Jul 20, 2016. Analyst had a consensus of $0.53. The company had revenue of $5333.00 million for the quarter, compared to analysts expectations of $5244.94 million. The company’s revenue was up 3.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.52 EPS.

Many Wall Street Analysts have commented on Abbott Laboratories. Abbott Laboratories was Upgraded by Edward Jones to ” Buy” on Jun 21, 2016.

Abbott Laboratories (Abbott) is engaged in the discovery development manufacture and sale of a range of health care products. Abbott operates in four business segments: Established Pharmaceutical Products Diagnostic Products Nutritional Products and Vascular Products. The Established Pharmaceutical Products segment includes the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment includes the sales of a line of adult and pediatric nutritional products. The Nutritional Products includes the sales of diagnostic systems and tests for blood banks hospitals commercial laboratories and alternate-care testing sites. The Vascular Products includes the sales of coronary endovascular structural heart vessel closure and other medical device products.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Abbott Laboratories - Is it time to Sell?

Top Brokerage Firms are advising their investors on Abbott Laboratories. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.